Diagnostic of heart failure

Patent metadata

Field	Value
Publication number	US-11061037-B2
Application number	US-201815869438-A
Country	US
Kind code	B2
Filing date	Jan 12, 2018
Priority date	Aug 9, 2012
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

Disclosed herein is a method for classifying a patient at risk for heart failure, wherein the method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from the patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.

First claim

The invention claimed is:

1. A method of treating heart failure in a patient in need thereof, comprising the steps of:
a) obtaining a biological sample from said patient;
b) measuring the concentration of IGFBP2 in the sample obtained in step a);
c) determining the severity of the heart failure depending on the concentration of IGFBP2 measured in step b); and
d) administering to said patient diagnosed as having heart failure an appropriate medication for a subject suffering from heart failure depending on the severity of the heart failure as determined in step c).

2. The method according to claim 1 , wherein the severity of the heart failure depending on the concentration of IGFBP2 measured in step b) is determined according to the NYHA heart failure classification.

3. The method according to claim 1 , wherein step b) is performed by measuring the level of IGFBP2 protein in the sample obtained in step a).

4. The method according to claim 1 , wherein the biological sample obtained in step a) is a urine sample.

5. The method according to claim 1 , wherein the biological sample obtained in step a) is a plasma sample.

6. The method according to claim 1 , wherein the biological sample obtained in step a) is a serum sample.

7. The method according to claim 1 , wherein the measuring of the concentration of IGFBP2 is performed by using a set of antibodies direct against IGFBP2.

8. The method according to claim 5 , wherein measuring the level of IGFBP2 protein is performed by ELISA.

Assignees

• Inst Nat Sante Rech Med
• Univ Toulouse 3 Paul Sabatier
• Ct Hospitalier Universitaire Toulouse
• Inserm Institut De La Sante Et De La Rech Medicale

Inventors

• Rouet Philippe
• Smih-Rouet Fatima
• Desmoulin Franck
• Galinier Michel

Classifications

• G01N27/447

  using electrophoresis · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N2333/4745

  Insulin-like growth factor binding protein · CPC title

• G01N27/4473

  by electric means · CPC title

• G01N33/6848

  Methods of protein analysis involving mass spectrometry · CPC title